VOQUEZNA achieved strong healing rates in all grades of Erosive GERD
Met the primary efficacy endpoint for healing: noninferiority vs lansoprazole
PRIMARY NONINFERIORITY ENDPOINT:
COMPLETE HEALING RATES BY WEEK 8
93% of VOQUEZNA
patients achieved healing
Observed healing rates in all grades of Erosive GERD at Week 2
SECONDARY ENDPOINT: COMPLETE HEALING RATES AT WEEK 2 FOR ALL GRADES1,2,*
*Endpoint not tested for statistical significance due to prespecified hierarchy and does not provide evidence of superiority.2
Observed healing rates in patients with moderate-to-severe Erosive GERD by Week 8
SECONDARY ENDPOINT: COMPLETE HEALING RATES BY WEEK 8 FOR GRADES C/D1,2,*,†
*Endpoint not tested for statistical significance due to prespecified hierarchy and does not provide evidence of superiority.
†Severity of the disease was classified based on the LA Classification Grading System (Grades A through D), with mild Erosive Esophagitis being Grades A or B and severe Erosive Esophagitis being Grades C or D.1,2
Superior healing rates vs lansoprazole in moderate-to-severe Erosive GERD at Week 2
SECONDARY SUPERIORITY ENDPOINT: COMPLETE HEALING RATES AT WEEK 2 FOR GRADES C/D1,2,*
*Severity of the disease was classified based on the LA Classification Grading System (Grades A through D), with mild Erosive Esophagitis being Grades A or B and severe Erosive Esophagitis being Grades C or D.1,2